open access

Vol 4, No 3 (2018)
Prace poglądowe
Published online: 2018-10-26
Get Citation

Serological markers in the diagnosis of rheumatoid arthritis — a clinician’s perspective

Cezary Iwaszkiewicz, Piotr Leszczyński
DOI: 10.5603/FR.2018.0005
·
Forum Reumatologiczne 2018;4(3):169-177.

open access

Vol 4, No 3 (2018)
Prace poglądowe
Published online: 2018-10-26

Abstract

The paper summarises the present knowledge of the role of autoantibodies in the diagnosis of rheumatoid arthritis. The starting point were the current rheumatoid arthritis classification criteria. The first part presents the diagnostic features of rheumatoid factor and anti-citrullinated protein/peptide antibodies, while the second part provides the answers to the essential clinical questions related to their use. This article, as opposed to more comprehensive papers in the field of immunology, focuses on daily rheumatological practice.

Forum Reumatol. 2018, tom 4, nr 3: 169–177

Abstract

The paper summarises the present knowledge of the role of autoantibodies in the diagnosis of rheumatoid arthritis. The starting point were the current rheumatoid arthritis classification criteria. The first part presents the diagnostic features of rheumatoid factor and anti-citrullinated protein/peptide antibodies, while the second part provides the answers to the essential clinical questions related to their use. This article, as opposed to more comprehensive papers in the field of immunology, focuses on daily rheumatological practice.

Forum Reumatol. 2018, tom 4, nr 3: 169–177

Get Citation

Keywords

rheumatoid arthritis; anti-citrullinated protein antibodies; ACPA; anti-cyclic citrullinated peptide antibodies; anti-CCP; aCCP; rheumatoid factor; RF

About this article
Title

Serological markers in the diagnosis of rheumatoid arthritis — a clinician’s perspective

Journal

Forum Reumatologiczne

Issue

Vol 4, No 3 (2018)

Pages

169-177

Published online

2018-10-26

DOI

10.5603/FR.2018.0005

Bibliographic record

Forum Reumatologiczne 2018;4(3):169-177.

Keywords

rheumatoid arthritis
anti-citrullinated protein antibodies
ACPA
anti-cyclic citrullinated peptide antibodies
anti-CCP
aCCP
rheumatoid factor
RF

Authors

Cezary Iwaszkiewicz
Piotr Leszczyński

References (64)
  1. Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E. Diagnosis and classification of rheumatoid arthritis. J Autoimmun. 2014; 48-49: 26–30.
  2. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6): 960–977.
  3. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol. 2010; 125(2 Suppl 2): S238–S247.
  4. Bonaguri C, Melegari A, Ballabio A, et al. Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results. Autoimmun Rev. 2011; 11(1): 1–5.
  5. Newkirk MM. Rheumatoid factors: what do they tell us? J Rheumatol. 2002; 29(10): 2034–2040.
  6. Nowak U, Gill K, Skamene E, et al. Rheumatoid factor induction in murine models of liver injury. Clin Exp Immunol. 2007; 147(2): 324–329.
  7. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69(9): 1580–1588.
  8. Deane KD. Preclinical rheumatoid arthritis (autoantibodies): an updated review. Curr Rheumatol Rep. 2014; 16(5): 419.
  9. Karimifar M, Moussavi H, Babaei M, et al. The association of immunoglobulin A, immunoglobulin G and anti-cyclic citrullinated peptide antibodies with disease activity in seronegative rheumatoid arthritis patients. J Res Med Sci. 2014; 19(9): 823–826.
  10. Rantapää-Dahlqvist S, de Jong BAW, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003; 48(10): 2741–2749.
  11. Nielen MMJ, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004; 50(2): 380–386.
  12. Majka DS, Deane KD, Parrish LA, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis. 2008; 67(6): 801–807.
  13. Kolfenbach JR, Deane KD, Derber LA, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 2010; 62(9): 2633–2639.
  14. Nell-Duxneuner V, Machold K, Stamm T, et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis. 2010; 69(1): 169–174.
  15. Carpenter L, Norton S, Nikiphorou E, et al. Early Rheumatoid Arthritis Study and the Early Rheumatoid Arthritis Network. Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. Arthritis Care Res (Hoboken). 2017; 69(12): 1809–1817.
  16. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007; 146(11): 797–808.
  17. Watanabe S, Gono T, Nishina K, et al. Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibody-associated vasculitis. BMC Immunol. 2017; 18(1): 53.
  18. Punzi L, Podswiadek M, Oliviero F, et al. Laboratory findings in psoriatic arthritis. Reumatismo. 2007; 59 Suppl 1: 52–55.
  19. Elkayam O, Segal R, Lidgi M, et al. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006; 65(8): 1110–1112.
  20. Schattner A, Shani A, Talpaz M, et al. Rheumatoid factors in the sera of patient with gastrointestinal carcinoma. Cancer. 1983; 52(11): 2156–2161.
  21. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013; 35(6): 727–734.
  22. Zengin O, Yıldız H, Demir ZH, et al. Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection: Review. Adv Clin Exp Med. 2017; 26(6): 987–990.
  23. Puszczewicz M, Iwaszkiewicz C. Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis. Arch Med Sci. 2011; 7(2): 189–194.
  24. Ludwig RJ, Vanhoorelbeke K, Leypoldt F, et al. Mechanisms of Autoantibody-Induced Pathology. Front Immunol. 2017; 8: 603.
  25. Infantino M, Manfredi M, Meacci F, et al. Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests. Clin Chim Acta. 2014; 436: 237–242.
  26. Ioan-Facsinay A, el-Bannoudi H, Scherer HU, et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis. 2011; 70(1): 188–193.
  27. Goules JD, Goules AV, Tzioufas AG. Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis. Clin Exp Immunol. 2013; 174(1): 10–17.
  28. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008; 58(10): 3000–3008.
  29. van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010; 69(8): 1554–1561.
  30. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 2013; 65(4): 899–910.
  31. Ménard HA. Anti-cyclic citrullinated peptide in preclinical rheumatoid arthritis. Food for thought. J Rheumatol. 2009; 36(4): 663–664.
  32. van Beers JJ, Willemze A, Jansen JJ, et al. ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res Ther. 2013; 15(5): R140.
  33. Willemze A, Böhringer S, Knevel R, et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis. 2012; 71(2): 268–274.
  34. van Venrooij WJ, van Beers JJ, Pruijn GJM. Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis. Ann N Y Acad Sci. 2008; 1143: 268–285.
  35. van Venrooij WJ, van Beers JJ, Pruijn GJM. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011; 7(7): 391–398.
  36. Payet J, Goulvestre C, Bialé L, et al. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. J Rheumatol. 2014; 41(12): 2395–2402.
  37. Vander Cruyssen B, Hoffman IEA, Zmierczak H, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 2005; 64(8): 1145–1149.
  38. Bogliolo L, Alpini C, Caporali R, et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol. 2005; 32(3): 511–515.
  39. Atzeni F, Sarzi-Puttini P, Lama N, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther. 2008; 10(3): R51.
  40. Payet J, Belkhir R, Gottenberg JE, et al. ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome? RMD Open. 2015; 1(1): e000066.
  41. Wang Y, Pei F, Wang X, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis. J Immunol Res. 2015; 2015: 915276.
  42. Lipinska J, Smolewska E, Brozik H, et al. Anti-CCP antibodies in children with juvenile idiopathic arthritis (JIA) - diagnostic and clinical significance. Centr. Eur. J. Immunol. . 2008; 33(1): 19–23.
  43. Popescu C, Zofotă S, Bojincă V, et al. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus. Rom J Intern Med. 2013; 51(3-4): 179–187.
  44. Kim JO, Lee JS, Choi JY, et al. The relationship between peripheral arthritis and anti-cyclic citrullinated peptide antibodies in ankylosing spondylitis. Joint Bone Spine. 2013; 80(4): 399–401.
  45. Labrador-Horrillo M, Martinez MaA, Selva-O'Callaghan A, et al. Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2009; 48(6): 676–679.
  46. Gokhan A, Turkeyler IH, Babacan T, et al. The antibodies cyclic citrullinated peptides (anti-CCP) positivity could be a promising marker in brucellosis patients presented with peripheric arthritis. Mod Rheumatol. 2014; 24(1): 182–187.
  47. Uyanik A, Albayrak F, Uyanik MH, et al. Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever. Rheumatol Int. 2010; 30(4): 467–471.
  48. Koga T, Migita K, Miyashita T, et al. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol. 2008; 26(1): 121–124.
  49. Santiago M, Baron M, Miyachi K, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol. 2008; 27(1): 77–83.
  50. Fusconi M, Vannini A, Dall'Aglio AC, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2005; 22(10): 951–955.
  51. Dalkılıç E, Öksüz MF, Tufan AN, et al. Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers. Eur J Rheumatol. 2015; 2(2): 62–65.
  52. Cunha BM, Mota LM, Pileggi GS, et al. HIV/AIDS and rheumatoid arthritis. Autoimmun Rev. 2015; 14(5): 396–400.
  53. Kakumanu P, Yamagata H, Sobel ES, et al. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008; 58(6): 1576–1581.
  54. Laustriat G, Ruyssen-Witrand A, Constantin A, et al. Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning. Joint Bone Spine. 2018; 85(2): 147–153.
  55. Iwaszkiewicz C, Puszczewicz M, Białkowska-Puszczewicz G. Diagnostic value of the anti-Sa antibody compared with the anti-cyclic citrullinated peptide antibody in rheumatoid arthritis. Int. J. Rheum. Dis. . 2015; 18(1): 46–51.
  56. Dogan M, Kucuksarac S, Tufekci O. Comparison of the diagnostic values in rheumatoid arthritis: anti-CCP antibodies and other serological tests. Biomedical Research. 2014; 25(3): 381–386.
  57. National Institute for Health and Care Excellence. Draft for consultation: rheumatoid arthritis in adults: management. 2018. www.nice.org.uk/guidance/GID-NG10014/documents/draft-guideline..
  58. Barra L, Pope J, Bessette L, et al. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford). 2011; 50(2): 311–316.
  59. Burr ML, Viatte S, Bukhari M, et al. Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Res Ther. 2012; 14(3): R109.
  60. Vos I, Van Mol C, Trouw LA, et al. Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. Clin Rheumatol. 2017; 36(7): 1487–1492.
  61. Song JY, Li MX, Li S, et al. Diagnostic value of third generation anti-cyclic citrullinated peptide assay in rheumatoid factor negative rheumatoid arthritis. Int. J. Clin. Exp. Pathol. 2016; 9(10): 10728–10733.
  62. Pruijn GJm, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. 2010; 12(1): 203.
  63. Li Y, Zhang R, Han Y, et al. Proficiency testing for the detection of anti-citrullinated protein antibody in China. Clin Chim Acta. 2015; 450: 67–71.
  64. Singh Sangha M, Wright ML, Ciurtin C. Strongly positive anti-CCP antibodies in patients with sacroiliitis or reactive arthritis post-E. coli infection: A mini case-series based review. Int J Rheum Dis. 2018; 21(1): 315–321.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl